(Q35110917)

6 August 2017

1 reference

title

Treatment of gammaherpesvirus-related neoplastic disorders in the immunosuppressed host (English)

1 reference

6 August 2017

1 reference

immunocompromised host

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12704593

25 December 2023

author name string

Robert Yarchoan

series ordinal

2

1 reference

6 August 2017

Richard F. Little

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12704593

25 December 2023

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12704593

25 December 2023

publication date

1 April 2003

1 reference

6 August 2017

Seminars in Hematology

1 reference

6 August 2017

40

1 reference

6 August 2017

2

1 reference

6 August 2017

163-171

1 reference

Indocyanine green and laser light for the treatment of AIDS-associated cutaneous Kaposi's sarcoma

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Epstein-Barr virus as a therapeutic target in Hodgkin's disease and nasopharyngeal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Interferon-alpha as first-line therapy for treatment of multicentric Castleman's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Value of combined approach with thallium-201 single-photon emission computed tomography and Epstein-Barr virus DNA polymerase chain reaction in CSF for the diagnosis of AIDS-related primary CNS lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

1 reference

7 January 2021

Detection of viral interleukin-6 in Kaposi sarcoma-associated herpesvirus-linked disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

AIDS-associated non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Phase III vehicle-controlled, multi-centered study of topical alitretinoin gel 0.1% in cutaneous AIDS-related Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Kaposi's-sarcoma-associated herpesvirus in HIV-negative Kaposi's sarcoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

A clinical, molecular and cytogenetic study of 12 cases of human herpesvirus 8 associated primary effusion lymphoma in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Eradication of latent Epstein-Barr virus by hydroxyurea alters the growth-transformed cell phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Hypoxia induces lytic replication of Kaposi sarcoma-associated herpesvirus

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Hodgkin's disease in patients with HIV infection and in the general population: comparison of clinicopathological features and survival

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Methods and objectives of a large US multicenter case-control study of post-transplant lymphoproliferative disorder in renal transplant patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: a potential treatment strategy for Epstein-Barr virus--positive Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Human herpesvirus type-8 (HHV-8) in haematopoietic neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Molecular pathology of AIDS-related lymphomas. Biologic aspects and clinicopathologic heterogeneity

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

The enigmas of Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Clonality in Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Decreasing rates of Kaposi's sarcoma and non-Hodgkin's lymphoma in the era of potent combination anti-retroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Anti-CD20 monoclonal antibody (Rituximab) and Cidofovir as successful treatment of an EBV-associated lymphoma with CNS involvement

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Benign and malignant smooth muscle tumors containing Epstein-Barr virus in children with AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Epstein-Barr virus (EBV)-associated smooth-muscle tumor arising in a post-transplant patient treated successfully for two PT-EBV-associated large-cell lymphomas. Case report.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Radiotherapy in the management of epidemic Kaposi's sarcoma: a retrospective study of 643 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Primary effusion lymphoma (PEL) in HIV-negative patients--a distinct clinical entity

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Preliminary observations on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Radiotherapy of primary central nervous system lymphoma in patients with and without human immunodeficiency virus. Ten years of treatment experience at the University of California San Francisco

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Activity of thalidomide in AIDS-related Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Significance of serial real-time PCR monitoring of EBV genome load in living donor liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Pleural and peritoneal lymphoma among people with AIDS in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Association of Epstein-Barr virus with leiomyosarcomas in young people with AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Lymphomas in patients with connective tissue disease. Comparison of p53 protein expression and latent EBV infection in patients immunosuppressed and not immunosuppressed with methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Epstein--Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Long-term remission of Kaposi's sarcoma following foscarnet treatment in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Epstein-Barr virus and human immunodeficiency virus serological responses and viral burdens in HIV-infected patients treated with HAART.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Monoclonal Origin of Multicentric Kaposi's Sarcoma Lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Treatment of AIDS-related primary central nervous system lymphoma with zidovudine, ganciclovir, and interleukin 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Epstein-Barr virus-associated smooth muscle tumors in ataxia-telangiectasia: a case report and review

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Kaposi's sarcoma-associated herpesvirus LANA2 is a B-cell-specific latent viral protein that inhibits p53

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Treatment of lymphoid malignancies in patients with ataxia-telangiectasia

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

A histone deacetylase inhibitor, azelaic bishydroxamic acid, shows cytotoxicity on Epstein-Barr virus transformed B-cell lines: a potential therapy for posttransplant lymphoproliferative disease

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Epstein-Barr virus-targeted therapy for AIDS-related primary lymphoma of the central nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

HHV-8 infection status of AIDS-unrelated and AIDS-associated multicentric Castleman's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Liposomal daunorubicin in the treatment of relapsed or refractory non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Vinblastine therapy for Kaposi's sarcoma in the acquired immunodeficiency syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Pretransplantation assessment of the risk of lymphoproliferative disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Cellular tropism and viral interleukin-6 expression distinguish human herpesvirus 8 involvement in Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

Infusional CDE with rituximab for the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: preliminary results of a phase I/II study

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970008-0

7 January 2021

10.1016/S0037-1963(03)70008-0

Identifiers

DOI

1 reference

6 August 2017

10.1053/SHEM.2003.50016

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12704593

25 December 2023

1 reference